In this episode, we meet Leo Grady, CEO of Paige. Paige is a global leader in AI-based software in pathology with a mission to drive the future of precision medicine. Paige is committed to transforming the diagnostics space by building an industry-leading portfolio of AI-based clinical applications, biomarkers and diagnostics.

Paige recently closed a $125 million Series C round, co-led by Casdin Capital, Johnson & Johnson Innovation and KKR, bringing the company’s total funding to $220 million since its launch in 2018. Paige has been honored as one of Fierce Medtech’s 2020 Fierce 15 companies and a New York Healthcare Innovation: Digital Health 100 Company.

Prior to joining Paige, Leo was the Senior Vice President of Engineering at HeartFlow, a medical technology company transforming the way cardiovascular disease is diagnosed and treated. Leo spent his early career at Siemens as a Principal Research Scientist and Line Manager, focusing on applying AI in clinical applications such as in vitro diagnostics. He holds a Ph.D. in Cognitive and Neural Systems from Boston University and a bachelor’s from the University of Vermont.

In this episode, Leo and I chat about:

The founding story of Paige and collaboration with Memorial Sloan Kettering Cancer Center
The trends and opportunities for digital innovation in the oncology pathology space, from screening/diagnosis to treatment selection and follow-up / monitoring
How Paige’s AI technology platform, built on millions of digitized tumor slides, enables pathologists to increase their diagnostic confidence and productivity
Leo’s reflections on driving change in healthcare

Leo Grady, Paige, on transforming precision medicine through AI